Noul Co. Ltd. announced that the results of a clinical performance study of its malaria diagnostic solution showed a sensitivity of 94.4%, and a specificity of 98.1%, which is almost equivalent to WHO-certified first-degree microscopy experts. Noul participated in the Multilateral Initiative on Malaria Pan-African Malaria Conference (MIM PAMC) held in Kigali, Rwanda from April 21 to 27, and reveals two of the latest clinical performance studies conducted with its malaria diagnostic solution 'miLab?

MAL', in three major African countries, Nigeria, Ethiopia, and Ghana, through a poster presentation. The study was conducted to verify the effectiveness of miLab? MAL's each use-case.

And as a result, miLab? MAL reached a sensitivity of 94.4% and a specificity of 98.1% for P. falciparum diagnosis, and a sensitivity of 97% and a specificity of 97.6% for P. vivax diagnosis. Based on these clinical achievements, Noul plans to actively promote cooperation with global research institutes and the health departments of each country.

The achievements through collaborative research are expected to be published as papers within the year. Meanwhile, the Multilateral Initiative on Malaria (MIM), established in 1997, is a global alliance of citizens, institutions, funding partners, and members united by the goal of enhancing scientific research capabilities in Africa and controlling and eradicating malaria. The Pan-African Malaria Conference (PAMC) is held every four years, marking its eighth anniversary this year.

Major sponsors include the Bill & Melinda Gates Foundation and the Medicine for Malaria Venture (MMV).